Oncology Resource Group

Oncology Competitive Intelligence Leaders

ASCO GU 2026 Analyst Briefing: Webinar

February 24, 2026

Sarah Lockhead, Ph.D.

Access Briefing

    Watch Now






    Executive Summary: ONCrg analyst Sarah Lockheed previews four late-breaking phase 3 readouts at ASCO GU 2026 covering the post-CPI RCC setting, adjuvant RCC, and perioperative and advanced bladder cancer — all centered on belzutifan combinations and the continued expansion of the enfortumab vedotin plus pembrolizumab franchise.

    • ASCO GU 2026
    • Video Event

      Sample Request

      How Did You Hear About Us

        Request Sample


        Please fill out the form below.

        We provide our samples for no charge to potential pharmaceutical clients, practicing physicians, and academic researchers.

        *Limited to one per year, other restrictions may apply.

        Select the Conferences of Interest:

          Request Planner


          Please fill out the form below.

          We provide our planners for no charge to potential pharmaceutical clients, practicing physicians, and academic researchers.

          *Limited to one per year, other restrictions may apply.

          Select the Conferences of Interest: